Pharmaceutical - Johnson & Johnson, Invokana


Current filters:

Johnson & JohnsonInvokana

Popular Filters

UK’s NICE backs Janssen’s Invokana for type 2 diabetes


Janssen, a subsidiary of US health care giant Johnson & Johnson, said today that it welcomes the publication…

DiabetesInvokanaJanssenJohnson & JohnsonPharmaceuticalPricingRegulationUK

NICE consults on draft guidance backing Invokana, as drug debuts in the UK


UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

J&J’s Invokana approved in Europe and Olysio cleared in USA

J&J’s Invokana approved in Europe and Olysio cleared in USA


It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries…

Anti-viralsDiabetesEuropeInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaOlysioPharmaceuticalRegulation

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide


Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA


There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

FDA panel backs J&J diabetes drug Invokana (canagliflozin)


The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

canagliflozinDiabetesInvokanaJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Back to top